Pharmaceutical - GSK

Filter

Current filters:

GSK

Popular Filters

Early results from GSK and NIH's Phase I Ebola vaccine show promise

Early results from GSK and NIH's Phase I Ebola vaccine show promise

27-11-2014

UK pharma major GlaxoSmithKline has reported promising preliminary results from a small Phase I trial…

Anti-viralsEbola vaccineGSKPharmaceuticalResearch

GSK COPD survey shows many sufferers underestimate the severity of their condition

GSK COPD survey shows many sufferers underestimate the severity of their condition

12-11-2014

UK pharma major GlaxoSmithKline has conducted a global survey of people living with chronic obstructive…

GlobalGSKPharmaceuticalResearchRespiratory and PulmonaryUnited States

UK's NICE recommends GSK's Arzerra for untreated chronic lymphocytic leukemia

UK's NICE recommends GSK's Arzerra for untreated chronic lymphocytic leukemia

04-11-2014

The UK’s National Institute for Health and Care Excellence has issued new preliminary draft guidance…

ArzerraGSKOfatumumab InjectionOncologyPharmaceuticalRegulationUK

Genmab transfers its ofatumumab collaboration from GSK to Novartis

Genmab transfers its ofatumumab collaboration from GSK to Novartis

03-11-2014

Danish biotech company Genmab has entered into an agreement with UK pharma major GlaxoSmithKline and…

DenmarkGenmabGSKNovartisOfatumumab InjectionOncologyPharmaceuticalResearch

Safety trials under way for GSK and Canadian Public Health Agency's Ebola vaccines

Safety trials under way for GSK and Canadian Public Health Agency's Ebola vaccines

27-10-2014

Safety trials are currently under way in two of the most advanced Ebola candidates, and the World Health…

Antibiotics and Infectious diseasesGSKPharmaceuticalResearchUKUSA

Saudi Arabian pharma needs to reconsider its business proposition to compete with global giants

Saudi Arabian pharma needs to reconsider its business proposition to compete with global giants

14-10-2014

The Saudi Arabian pharma market is a changing landscape in the face of the physical penetration of international…

GSKMarkets & MarketingPfizerPharmaceuticalSaudi Arabia

ERS 2014: GSK reports positive Phase III results of its mepolizumab in asthma

ERS 2014: GSK reports positive Phase III results of its mepolizumab in asthma

08-09-2014

UK pharma major GlaxoSmithKline has reported positive data from its Phase III asthma studies of mepolizumab,…

GlaxoSmithKlineGSKImmunosuppressantsmepolizumabMepolizumabPharmaceuticalResearchRespiratory and PulmonaryUK

GSK spies indicted in China for illegally obtaining information

GSK spies indicted in China for illegally obtaining information

15-07-2014

A couple allegedly working for UK pharma major GlaxoSmithKline in China have been indicted in Shanghai…

ChinaGlaxoSmithKlineGSKLegalPharmaceuticalXinhua News AgencyXinhua News Agency

ADA 2014: GSK presents new data for once-weekly Tanzeum in type 2 diabetes

ADA 2014: GSK presents new data for once-weekly Tanzeum in type 2 diabetes

15-06-2014

Patients enrolled in of four randomized Phase III studies who remained on Tanzeum/Eperzan (albiglutide),…

Anti-diabetic drugsDiabetesGlaxoSmithKlineGSKMajorPharmaceuticalResearchStudy protocolStudy protocolTanzeumUK

GSK faces fresh allegations of “inproper conduct” in Iraq

GSK faces fresh allegations of “inproper conduct” in Iraq

08-04-2014

UK pharma major GlaxoSmithKline is facing allegations of bribery in Iraq, less than a year after the…

ChinaGlaxoSmithKlineGSKIraqMajorPharmaceuticalRegulationUK

NHS England approves GSK’s Tafinlar for funding by UK’s Cancer Drugs Fund

NHS England approves GSK’s Tafinlar for funding by UK’s Cancer Drugs Fund

04-02-2014

GlaxoSmithKline’s Tafinlar (dabrafenib) is now available for metastatic melanoma patients in England…

FinancialGSKOncologyPharmaceuticalRegulationTafinlarUK

GSK stock will remain strong despite slowing emerging markets, say analysts

GSK stock will remain strong despite slowing emerging markets, say analysts

04-10-2013

Following concerns from Eli Lilly about the slowdown of emerging markets and devaluation of the Japanese…

EuropeFinancialGlaxoSmithKlineGSKPharmaceutical

Skyepharma's asthma drug helps revenues soar 58% in first half

15-08-2013

UK drug delivery specialist Skyepharma (LSE: SKP) has seen its first half revenues soar 58% to £31.3…

EuropeFinancialFlutiformGSKPharmaceuticalSkyepharma

GSK inks $300m rare diseases alliance with Angiochem

28-02-2012

GlaxoSmithKline has forged an R&D alliance with Montreal, Canada-based Angiochem that will focus on the…

AngiochemCerezymeGenzymeGSKNeurologicalPharmaceuticalRare diseasesShireVpriv

Back to top